お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
726452

世界のハンチントン病治療市場の分析と予測:治療法(対症療法、疾患修飾療法)、主要市場別 2018年~2023年

Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Therapy, Disease-modifying Therapy), By Major Markets, And Segment Forecasts, 2018 - 2023

出版日: | 発行: Grand View Research, Inc. | ページ情報: 英文 89 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.84円
世界のハンチントン病治療市場の分析と予測:治療法(対症療法、疾患修飾療法)、主要市場別 2018年~2023年
出版日: 2018年08月22日
発行: Grand View Research, Inc.
ページ情報: 英文 89 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のハンチントン病治療市場は、2018年から2023年にかけて38.2%のCAGRで推移し、2023年までに15億米ドル規模の市場に成長することが予測されています。疾患修飾療法の急速な普及、新治療薬の採用の増加、研究開発活動の増加などによって当市場の成長が促進されています。

当レポートでは、世界のハンチントン病治療市場を調査し、市場および疫学の概要、市場動向、市場規模の推移と予測、市場の成長要因および阻害要因の分析、市場機会、パイプライン情報、革新的な治療薬の概要、市場シェア、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査方法

  • 情報調達
  • 情報分析

第2章 エグゼクティブサマリー

第3章 疾患のプライマーと疫学

  • 疾患のプライマー

第4章 世界のハンチントン病治療市場の概要

  • ハンチントン病の治療クラス
  • 市場分析:治療法別
  • 販売実績:治療法別
  • 市場分析:投与経路別
  • 市場規模の推移と予測
  • 市場規模の推移と予測:主要7市場別
  • 市場シェア:企業別
  • 市場力学とブランド戦略
  • 特許権の存続期間
  • ハンチントン病治療薬市場:成長要因と阻害要因
  • M&A、取引の情勢
  • 価格設定および償還シナリオ
  • SWOT分析

第5章 ハンチントン病治療市場:パイプライン情報

  • パイプライン概要
  • 研究開発の動向
  • 革新的治療薬の概要
  • 世界のパイプライン予測

第6章 企業プロファイル

  • Valeant Pharmaceuticals
  • Teva Pharmaceuticals
  • Ionis Pharmaceuticals
  • Wave Life Sciences
  • Horizon Pharma
  • Prana Biotech

第7章 市場の見通し

  • 市場の将来展望
  • 勝者と敗者
  • 新興企業/新技術プラットフォーム
  • 市場の見通し
図表

List of Tables

  • TABLE 1 Huntington's Disease - Classification based on CAG Repeats
  • TABLE 2 Huntington's Disease - Prevalence
  • TABLE 3 Huntington's Disease - Incidence (New cases)
  • TABLE 4 Antidopaminergics - Drugs Specifically Approved for Huntington's disease
  • TABLE 5 Drugs Prescribed Off - label for Huntington's Disease
  • TABLE 6 Sales by Treatment Type, in $ Million, 2017 - 2023
  • TABLE 7 Sales Performance by Geographic Markets, in $ Million, 2017 - 2023
  • TABLE 8 U.S., Sales by Treatment (2017 - 2023)
  • TABLE 9 U.K., Sales by Treatment (2017 - 2023)
  • TABLE 10 Germany, Sales by Treatment (2017 - 2023)
  • TABLE 11 France, Sales by Treatment (2017 - 2023)
  • TABLE 12 Italy, Sales by Treatment (2017 - 2023)
  • TABLE 13 Spain, Sales by Treatment (2017 - 2023)
  • TABLE 14 Japan, Sales by Treatment (2017 - 2023)
  • TABLE 15 Patent Expiry Analysis
  • TABLE 16 U.S. Patents for Austedo
  • TABLE 17 R&D Pipeline Overview - Active Clinical Trials in Huntington's Disease
  • TABLE 18 Gene - Silencing Therapies Under Development for Huntington's Disease
  • TABLE 19 Late Stage Pipeline Analysis
  • TABLE 20 Nerventra (laquinimod)
  • TABLE 21 VX - 15
  • TABLE 22 Cellavita HD
  • TABLE 23 AMT - 130
  • TABLE 24 Pipeline Forecast
  • TABLE 25 Valeant Pharma Product Forecast Sales (2017 - 2023)
  • TABLE 26 Teva Pharmaceuticals Product Forecast Sales (2017 - 2023)
  • TABLE 27 Horizon Pharma Product Forecast Sales (2017 - 2023)
  • TABLE 28 Prana Biotech - Product Forecast Sales (2017 - 2023)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 U.S. - Mortality due to Huntington's disease (Rate/ 100,000)
  • FIG. 8 Therapy Type, Market Share Distribution, 2017 and 2023
  • FIG. 9 Market, by Mode of Administration, 2017 & 2023
  • FIG. 10 Regional Market Size, 2017 & 2023
  • FIG. 11 Market Shares Distribution, by Company (2017 & 2023)
  • FIG. 12 Huntington's Disease Therapeutic Sector SWOT
  • FIG. 13 Huntington's Disease R&D Pipeline - Drugs in Development
  • FIG. 14 Huntington's Disease R&D Pipeline, by Treatment Type
  • FIG. 15 Valeant Pharma HD Sales Forecast
  • FIG. 16 Valeant SWOT Analysis
  • FIG. 17 Teva HD Sales Forecast
  • FIG. 18 Teva SWOT Analysis
  • FIG. 19 Ionis Pharmaceuticals Sales Forecast
  • FIG. 20 Ionis Pharmaceuticals SWOT Analysis
  • FIG. 21 Wave Life Sciences HD Sales Forecast
  • FIG. 22 Wave Life Sciences SWOT Analysis
  • FIG. 23 Horizon Pharma HD Sales Forecast
  • FIG. 24 Horizon Pharma SWOT Analysis
  • FIG. 25 Prana Biotech HD Sales Forecast
  • FIG. 26 Prana Biotech SWOT Analysis
目次
Product Code: GVR-2-68038-552-6

The global huntington's disease treatment market size is expected to be valued at USD 1.5 billion by 2023, as per a new report by Grand View Research, Inc., registering a CAGR of 38.2% during the forecast period. The market is largely driven by factors such as rapid uptake of disease-modifying therapies, increased adoption of novel therapeutics, and increase in R&D activities.

Huntington's disease is an inherited neurodegenerative disorder characterized by a combination of motor, cognitive, and psychiatric symptoms. Currently, only two symptom-alleviating therapies are specifically approved for this disorder: Xenazine and Austedo. Off-label medications are used extensively due to lack of approved alternatives.

The pipeline for Huntington's disease is expected to witness rapid developments in the coming years as disease-modifying drugs transform the market landscape. Improved disease understanding has led to significant progress in the development of therapeutic approaches aimed at modifying specific changes linked to the causative mutation. The potential role of RNA antisense technology and stem cell therapy are under active clinical investigation. Wave Life Sciences and Ionis Pharma's antisense oligonucleotides aim to target underlying disease cause and are expected to contribute significantly to market growth.

Further key findings from the report suggest:

  • Teva is projected to become the market leader, capturing more than 45% of the market in 2023, driven by Austedo's rapid uptake and improved efficacy profile compared to its competitors. Teva's Huntexil is expected to be the only new symptom-alleviating drug to be launched during the forecast period
  • Raptor's RP103 is expected to face head-to-head competition from Prana Biotech's Phase II drug PBT2 to be the first disease modifying therapy to be launched in the market
  • Currently, 23 products are under clinical investigation for Huntington's disease, out of which, one is in Phase II/III each, thirteen in Phase II trials, two in Phase Ib/IIa, six in pre-clinical trials, and one in discovery phase
  • EU5 will remain the second largest market with more than 15% share in 2023, driven by rising disease prevalence, novel drug launches, and increase in R&D activities
  • Companies are now focusing on development of treatments that can be injected directly in the brain to directly inhibit the formation of mutant HTT protein, instead of targeting the mutant protein

Drugs with novel targets in early-phase development include: Stealth Biotherapeutics' SBT-20 (mitochondria-targeted cytoprotective peptide), Cellavita + Azidus Brazil's Cellavita HD (stem cell therapy), Sangamo/ Shire's mHTT ZFP (zinc finger protein), and UniQure's AMT-130 (gene therapy).

Table of Contents

Chapter 1 Research Methodology

  • 1.1. Information procurement
  • 1.2. Information or Data Analysis
    • 1.2.1. Market Formulation & Validation

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology

  • 3.1 Disease Primer
    • 3.1.1 Molecular Biology and Genetics of Huntington Disease (HD)
    • 3.1.2 Signs and Symptoms
    • 3.1.3 Biomarkers
    • 3.1.4 Current Prevalence and Incidence Rate for Seven Major Markets (U.S., Japan, EU5)

Chapter 4 Global Huntington's Disease Treatment Market Overview

  • 4.1 Therapeutic Classes for HD
  • 4.2 Market, by Treatment
  • 4.3 Sales Performance, by Treatment (2017 - 2023)
    • 4.3.1 Symptomatic Therapy
    • 4.3.2 Disease - Modifying Therapy
  • 4.4 Market, by Mode of Administration
  • 4.5 Market Size and Forecast (2017 - 2023)
  • 4.6 Market Size and Forecast, by Seven Major Markets (2017 - 2023)
    • 4.6.1 U.S., Sales by Treatment (2017 - 2023)
    • 4.6.2 U.K., Sales by Treatment (2017 - 2023)
    • 4.6.3 Germany, Sales by Treatment (2017 - 2023)
    • 4.6.4 France, Sales by Treatment (2017 - 2023)
    • 4.6.5 Italy, Sales by Treatment (2017 - 2023)
    • 4.6.6 Spain, Sales by Treatment (2017 - 2023)
    • 4.6.7 Japan, Sales by Treatment (2017 - 2023)
  • 4.7 Market Share Distribution, by Company (2017 - 2023)
  • 4.8 Market Dynamics and Brand Strategies
  • 4.9 Patent Expiry Analysis
  • 4.10 Huntington's Disease Treatment Market: Drivers and Restraints
    • 4.10.1 Market Drivers
    • 4.10.2 Market Restraints
  • 4.11 M&A, Deal Landscape (2013 - 2018 YTD)
    • 4.11.1 Mergers & Acquisitions
    • 4.11.2 Deals Landscape
  • 4.12 Pricing and Reimbursement Scenario
  • 4.13 Huntington's Disease Sector SWOT

Chapter 5 Huntington's Disease Treatment Market: Pipeline Intelligence

  • 5.1 Pipeline Landscape
    • 5.1.1 Leading Drugs in Development
  • 5.2 Key R&D Trends
    • 5.2.1 Gene Therapy
      • 5.2.1.1 Antisense Oligonucleotides (ASO)
      • 5.2.1.2 Gene Therapy with miRNAs
      • 5.2.1.3 mRNA Splicing (Splicing Interference)
      • 5.2.1.4 Zinc - Finger DNA Binding Protein (ZFP)
    • 5.2.2 Stem Cell Therapy
    • 5.2.3 Small Molecules
  • 5.3 Pipeline Landscape
    • 5.3.1 Late Stage Pipeline Drugs
  • 5.4 Clinical Profiles of Disruptive Drugs
  • 5.5 Global Pipeline Forecast

Chapter 6 Company Profiles

  • 6.1 Valeant Pharmaceuticals
    • 6.1.1 Company Overview
    • 6.1.2 Product Portfolio - Xenazine (tetrabenazine)
    • 6.1.3 Product Forecast Sales through 2023
    • 6.1.4 Strategic Initiatives
      • 6.1.4.1 Key Company News Flow
    • 6.1.5 SWOT
  • 6.2 Teva Pharmaceuticals
    • 6.2.1 Company Overview
    • 6.2.2 Product Portfolio - Austedo (deutetrabenazine)
    • 6.2.3 Product Forecast Sales through 2023
    • 6.2.4 Strategic Initiatives
      • 6.2.4.1 Key Company News Flow
    • 6.2.5 Pipeline Analysis and Overview
      • 6.2.5.1 Catalysts and Event Calendar
    • 6.2.6 SWOT
  • 6.3 Ionis Pharmaceuticals
    • 6.3.1 Company Overview
    • 6.3.2 Product Portfolio - IONIS - HTTRx/ RG6042
    • 6.3.3 Product Forecast Sales through 2023
    • 6.3.4 Strategic Initiatives
      • 6.3.4.1 Key Company News Flow
      • 6.3.4.2 Catalysts & Events Calendar
    • 6.3.5 SWOT
  • 6.4 Wave Life Sciences
    • 6.4.1 Company Overview
    • 6.4.2 Product Portfolio - WVE - 120101 and WVE - 120102
    • 6.4.3 Product Forecast Sales through 2023
    • 6.4.4 Strategic Initiatives
      • 6.4.4.1 Key Company News Flow
      • 6.4.4.2 Catalysts & Events Calendar
    • 6.4.5 SWOT
  • 6.5 Horizon Pharma
    • 6.5.1 Company Overview
    • 6.5.2 Product Portfolio - Procysbi (RP103)
    • 6.5.3 Product Forecast Sales through 2023
    • 6.5.4 Strategic Initiatives
      • 6.5.4.1 Key Company News Flow
    • 6.5.5 SWOT
  • 6.6 Prana Biotech
    • 6.6.1 Company Overview
    • 6.6.2 Product Portfolio - PBT2
    • 6.6.3 Product Forecast Sales through 2023
    • 6.6.4 Strategic Initiatives
      • 6.6.4.1 Key Company News Flow
    • 6.6.5 SWOT

Chapter 7 Market Outlook

  • 7.1. What the Future Holds
  • 7.2. The Winners and Losers
    • 7.2.1. Winners
    • 7.2.2. Losers
  • 7.3. Emerging Companies/New Technology Platforms
    • 7.3.1. Vaccinex
    • 7.3.2. UniQure
    • 7.3.3. Stealth BioTherapeutics
    • 7.3.4. Azevan Pharmaceuticals
    • 7.3.5. Voyager Therapeutics
    • 7.3.6. Sangamo/ Shire
  • 7.4. The Road Ahead
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.